Ignite Creation Date:
2024-05-06 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 12:47 PM
Study NCT ID:
NCT03559686
Status:
AVAILABLE
Last Update Posted:
2023-08-01
First Post:
2018-06-05
Brief Title:
Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis RA
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Arthritis RA Who Participated in Open Label Studies C87015 C87028 and C87051
Status:
AVAILABLE
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this Named Patient Program NPP is to provide continued availability of Certolizumab Pegol CZP to adult Rheumatoid Arthritis RA patients who participated in the open label studies C87015 CDP870 015 C87028 CDP870-028 and C87051 CDP870-051 Physicians may use the option to continue offering patients CZP treatment or to transition patients off CZP to a standard care regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None